Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subhashis Banerjee

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
Arthritis Care & Research|September 25, 2019
Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor PrognosisHarris A Ahmad, Joshua F Baker, Mikkel Østergaard, et al.
Rheumatology (Oxford, England)|October 18, 2024
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trialArthur Kavanaugh, Laura C Coates, Philip J Mease, et al.
Molecular Neurobiology|May 2, 2024
Biochemical, Biomarker, and Behavioral Characterization of the Grn<sup>R493X</sup> Mouse Model of Frontotemporal DementiaDenise M Smith, Geetika Aggarwal, Michael L Niehoff, et al.
The New England Journal of Medicine|September 13, 2018
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in PsoriasisKim Papp, Kenneth Gordon, Diamant Thaçi, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid ArthritisMark C Genovese, Daniel K Braun, Janelle S Erickson, et al.
The Journal of Biological Chemistry|May 30, 2014
Structure of REV-ERBβ ligand-binding domain bound to a porphyrin antagonistEdna Matta-Camacho, Subhashis Banerjee, Travis S Hughes, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
Biochemical, biomarker, and behavioral characterization of the <i>Grn</i><sup></sup> mouse model of frontotemporal dementiaDenise M Smith, Geetika Aggarwal, Michael L Niehoff, et al.
Lupus Science & Medicine|June 1, 2025
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trialMarta Mosca, Laurent Arnaud, Anca Askanase, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 4, 2015
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging studyMichael E Weinblatt, Philip Mease, Eduardo Mysler, et al.
RMD Open|June 28, 2019
Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a <i>post hoc</i> analysis of a phase III trialIain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Arthritis Care & Research|September 25, 2019
Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor PrognosisHarris A Ahmad, Joshua F Baker, Mikkel Østergaard, et al.
Rheumatology (Oxford, England)|October 18, 2024
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trialArthur Kavanaugh, Laura C Coates, Philip J Mease, et al.
Molecular Neurobiology|May 2, 2024
Biochemical, Biomarker, and Behavioral Characterization of the Grn<sup>R493X</sup> Mouse Model of Frontotemporal DementiaDenise M Smith, Geetika Aggarwal, Michael L Niehoff, et al.
The New England Journal of Medicine|September 13, 2018
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in PsoriasisKim Papp, Kenneth Gordon, Diamant Thaçi, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid ArthritisMark C Genovese, Daniel K Braun, Janelle S Erickson, et al.
The Journal of Biological Chemistry|May 30, 2014
Structure of REV-ERBβ ligand-binding domain bound to a porphyrin antagonistEdna Matta-Camacho, Subhashis Banerjee, Travis S Hughes, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
Biochemical, biomarker, and behavioral characterization of the <i>Grn</i><sup></sup> mouse model of frontotemporal dementiaDenise M Smith, Geetika Aggarwal, Michael L Niehoff, et al.
Lupus Science & Medicine|June 1, 2025
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trialMarta Mosca, Laurent Arnaud, Anca Askanase, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 4, 2015
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging studyMichael E Weinblatt, Philip Mease, Eduardo Mysler, et al.
RMD Open|June 28, 2019
Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a <i>post hoc</i> analysis of a phase III trialIain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, et al.
Pageof 12